ATC Group: J05AP09 Dasabuvir

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AP09 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AP Antivirals for treatment of HCV infections
5 J05AP09

Active ingredients in J05AP09

Active Ingredient Description
Dasabuvir

Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir combines three direct-acting antiviral medicinal products with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle.

Related product monographs

Title Information Source Document Type  
EXVIERA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Cyprus (CY)

Estonia (EE)

Finland (FI)

Ireland (IE)

Lithuania (LT)

Poland (PL)

Romania (RO)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.